Anika Therapeutics (ANIK) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $23.1 million.
- Anika Therapeutics' Receivables - Net fell 2544.7% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year decrease of 2544.7%. This contributed to the annual value of $24.3 million for FY2024, which is 999.78% down from last year.
- Per Anika Therapeutics' latest filing, its Receivables - Net stood at $23.1 million for Q3 2025, which was down 2544.7% from $24.8 million recorded in Q2 2025.
- Anika Therapeutics' 5-year Receivables - Net high stood at $38.4 million for Q2 2023, and its period low was $22.7 million during Q1 2025.
- Moreover, its 5-year median value for Receivables - Net was $31.1 million (2021), whereas its average is $30.3 million.
- Its Receivables - Net has fluctuated over the past 5 years, first soared by 4060.58% in 2021, then plummeted by 3270.19% in 2025.
- Over the past 5 years, Anika Therapeutics' Receivables - Net (Quarter) stood at $31.3 million in 2021, then grew by 15.82% to $36.2 million in 2022, then decreased by 25.41% to $27.0 million in 2023, then decreased by 10.0% to $24.3 million in 2024, then fell by 5.21% to $23.1 million in 2025.
- Its last three reported values are $23.1 million in Q3 2025, $24.8 million for Q2 2025, and $22.7 million during Q1 2025.